Page 10 of 13 – SEC Filing
CUSIP No. 68210P107
13D/A Page 10 of 13
Item 1. Security and Issuer.
This Amendment No. 4 amends
the Statement of Beneficial Ownership on Schedule 13D originally filed with the Securities and Exchange Commission
(the “Commission”) on August 11, 2015 and as amended by Amendment No. 1, filed on October 8, 2015, as amended
by Amendment No. 2, filed on November 17, 2015, and as further amended by Amendment No. 3, filed on March 1, 2016
(collectively, the “Schedule 13D”) by the Wynnefield Reporting Persons (as defined in the Schedule 13D) with
respect to shares of common stock, $0.01 par value per share (the “Common Stock”) of Omega Protein Corporation, a
Nevada corporation (the “Issuer”). The Issuer maintains its principal executive office at 2105 City West Blvd.,
Suite 500, Houston, Texas 77042. Unless specifically amended hereby, the disclosures set forth in the Schedule 13D shall
remain unchanged. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Schedule
13D.
Item 3. Source and Amount of Funds or
Other Consideration.
Item 3 of the Schedule 13D is hereby amended and restated
as follows:
The securities reported in this Schedule
13D/A as directly beneficially owned by the Wynnefield Reporting Persons were acquired with funds of approximately $20,872,731 (including
brokerage commissions). All such funds were provided from the working capital or personal funds of the Wynnefield Reporting Persons
who directly beneficially own such securities.
Item 4. Purpose of the Transaction
Item 4 of the Schedule 13D is hereby amended by the addition
of the following:
This Amendment No. 4 to Schedule 13D is being filed to
disclose that the Wynnefield Reporting Persons have increased their beneficial ownership in the Issuer’s Common
Stock due to the Wynnefield Reporting Persons’ belief that the Issuer’s Common Stock is currently undervalued.
Follow Omega Protein Corp (NYSE:OME)
Follow Omega Protein Corp (NYSE:OME)
We may use your email to send marketing emails about our services. Click here to read our privacy policy.
| CUSIP No. 68210P107 | 13D/A | Page 10 of 13 |
Item 1. Security and Issuer.
This Amendment No. 4 amends
the Statement of Beneficial Ownership on Schedule 13D originally filed with the Securities and Exchange Commission
(the “Commission”) on August 11, 2015 and as amended by Amendment No. 1, filed on October 8, 2015, as amended
by Amendment No. 2, filed on November 17, 2015, and as further amended by Amendment No. 3, filed on March 1, 2016
(collectively, the “Schedule 13D”) by the Wynnefield Reporting Persons (as defined in the Schedule 13D) with
respect to shares of common stock, $0.01 par value per share (the “Common Stock”) of Omega Protein Corporation, a
Nevada corporation (the “Issuer”). The Issuer maintains its principal executive office at 2105 City West Blvd.,
Suite 500, Houston, Texas 77042. Unless specifically amended hereby, the disclosures set forth in the Schedule 13D shall
remain unchanged. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Schedule
13D.
Item 3. Source and Amount of Funds or
Other Consideration.
Item 3 of the Schedule 13D is hereby amended and restated
as follows:
The securities reported in this Schedule
13D/A as directly beneficially owned by the Wynnefield Reporting Persons were acquired with funds of approximately $20,872,731 (including
brokerage commissions). All such funds were provided from the working capital or personal funds of the Wynnefield Reporting Persons
who directly beneficially own such securities.
Item 4. Purpose of the Transaction
Item 4 of the Schedule 13D is hereby amended by the addition
of the following:
This Amendment No. 4 to Schedule 13D is being filed to
disclose that the Wynnefield Reporting Persons have increased their beneficial ownership in the Issuer’s Common
Stock due to the Wynnefield Reporting Persons’ belief that the Issuer’s Common Stock is currently undervalued.
